Fosdenopterin approved to treat adult patients with molybdenum cofactor deficiency (MoCD) Type A

The Medicines and Healthcare products Regulatory Agency (MHRA) has today (9 April 2024) approved the medicine fosdenopterin (Nulibry) to treat the genetic disease Molybdenum Cofactor Deficiency (MoCD) Type A

Follow this news feed: